Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

CureVac AG. (11/20/19). "Press Release: CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference". Tübingen & Boston, MA.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 Solebury Trout
Products Product Piper Jaffray Annual Healthcare Conference 2019 New York
  Product 2 mRNA-based drug
Index term Index term CureVac–Piper Jaffray: investor conference, 201912 supply service CureVac presents at Piper Jaffray Healthcare Conference 2019
Persons Person Menichella, Daniel L. (Dan) (CureVac 201806– CEO joined 201705 as CEO CureVac Inc before Bamboo Therapeutics)
  Person 2 Hoffmann, Thomas (Trout Group 201412)
     


CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief Executive Officer, Dan Menichella, will present a corporate overview at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 3, 2019.

The company will also be holding one-on-one meetings. Interested parties can contact Thomas Hoffmann (thoffmann@soleburytrout.com) to schedule a meeting with CureVac representatives during the conference.


About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years of expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. To date, CureVac has received approximately $420 million (€400 million) in equity investments, including significant investments from SAP founder Dietmar Hopp’s dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.


***


Media Contact

Thorsten Schüller, Corporate Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com

Investor Relations Contact

Thomas Hoffmann
Solebury Trout
T: +1 646-378-2931
thoffmann@soleburytrout.com

   
Record changed: 2019-12-23

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

More documents for CureVac (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75




» top